pubmed-article:2511020 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:2511020 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
pubmed-article:2511020 | lifeskim:mentions | umls-concept:C0039601 | lld:lifeskim |
pubmed-article:2511020 | lifeskim:mentions | umls-concept:C0023779 | lld:lifeskim |
pubmed-article:2511020 | lifeskim:mentions | umls-concept:C0003591 | lld:lifeskim |
pubmed-article:2511020 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
pubmed-article:2511020 | lifeskim:mentions | umls-concept:C0559956 | lld:lifeskim |
pubmed-article:2511020 | pubmed:issue | 5 | lld:pubmed |
pubmed-article:2511020 | pubmed:dateCreated | 1990-1-10 | lld:pubmed |
pubmed-article:2511020 | pubmed:abstractText | Ten men with Klinefelter's syndrome were studied to assess the effect of testosterone replacement on plasma lipids and apolipoproteins. Measurements taken before the insertion of a testosterone ester implant were compared with those obtained 1 week and 4 weeks later. Mean plasma testosterone, androstenedione, total cholesterol and calculated LDL-cholesterol increased significantly after 1 and 4 weeks. No significant changes were seen in total plasma concentrations of HDL-cholesterol, HDL-cholesterol subfractions 2 and 3 or in apoplipoproteins A-I, A-II or B. A significant correlation was seen between total cholesterol and plasma oestradiol concentrations (Rs = 0.61; P less than 0.001). A significant negative correlation was seen between the concentrations of total testosterone and total triglyceride (Rs = -0.56; P less than 0.005) but not with the other lipid parameters. Testosterone replacement is associated with slight but potentially adverse changes in plasma cholesterol levels. | lld:pubmed |
pubmed-article:2511020 | pubmed:language | eng | lld:pubmed |
pubmed-article:2511020 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2511020 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:2511020 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2511020 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2511020 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2511020 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2511020 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2511020 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:2511020 | pubmed:month | Oct | lld:pubmed |
pubmed-article:2511020 | pubmed:issn | 0014-2972 | lld:pubmed |
pubmed-article:2511020 | pubmed:author | pubmed-author:WenhamP RPR | lld:pubmed |
pubmed-article:2511020 | pubmed:author | pubmed-author:ShepherdJJ | lld:pubmed |
pubmed-article:2511020 | pubmed:author | pubmed-author:BeastallG HGH | lld:pubmed |
pubmed-article:2511020 | pubmed:author | pubmed-author:PriceW HWH | lld:pubmed |
pubmed-article:2511020 | pubmed:author | pubmed-author:EdwardsC RCR | lld:pubmed |
pubmed-article:2511020 | pubmed:author | pubmed-author:JonesD BDB | lld:pubmed |
pubmed-article:2511020 | pubmed:author | pubmed-author:HornD BDB | lld:pubmed |
pubmed-article:2511020 | pubmed:author | pubmed-author:HigginsBB | lld:pubmed |
pubmed-article:2511020 | pubmed:author | pubmed-author:SweetingV MVM | lld:pubmed |
pubmed-article:2511020 | pubmed:author | pubmed-author:BilletJ SJS | lld:pubmed |
pubmed-article:2511020 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:2511020 | pubmed:volume | 19 | lld:pubmed |
pubmed-article:2511020 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:2511020 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:2511020 | pubmed:pagination | 438-41 | lld:pubmed |
pubmed-article:2511020 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
pubmed-article:2511020 | pubmed:meshHeading | pubmed-meshheading:2511020-... | lld:pubmed |
pubmed-article:2511020 | pubmed:meshHeading | pubmed-meshheading:2511020-... | lld:pubmed |
pubmed-article:2511020 | pubmed:meshHeading | pubmed-meshheading:2511020-... | lld:pubmed |
pubmed-article:2511020 | pubmed:meshHeading | pubmed-meshheading:2511020-... | lld:pubmed |
pubmed-article:2511020 | pubmed:meshHeading | pubmed-meshheading:2511020-... | lld:pubmed |
pubmed-article:2511020 | pubmed:meshHeading | pubmed-meshheading:2511020-... | lld:pubmed |
pubmed-article:2511020 | pubmed:meshHeading | pubmed-meshheading:2511020-... | lld:pubmed |
pubmed-article:2511020 | pubmed:meshHeading | pubmed-meshheading:2511020-... | lld:pubmed |
pubmed-article:2511020 | pubmed:meshHeading | pubmed-meshheading:2511020-... | lld:pubmed |
pubmed-article:2511020 | pubmed:meshHeading | pubmed-meshheading:2511020-... | lld:pubmed |
pubmed-article:2511020 | pubmed:meshHeading | pubmed-meshheading:2511020-... | lld:pubmed |
pubmed-article:2511020 | pubmed:year | 1989 | lld:pubmed |
pubmed-article:2511020 | pubmed:articleTitle | The effect of testosterone replacement on plasma lipids and apolipoproteins. | lld:pubmed |
pubmed-article:2511020 | pubmed:affiliation | Department of Medicine, Western General Hospital, Edinburgh, UK. | lld:pubmed |
pubmed-article:2511020 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2511020 | lld:pubmed |